NCT03207347 2023-09-15A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)University of FloridaPhase 2 Completed37 enrolled 15 charts
NCT05429866 2023-03-08Immunological Variables Associated to ICI Toxicity in Cancer PatientsJules Bordet InstitutePhase 2 Unknown441 enrolled
NCT02599194 2019-01-0318F-FSPG PET/CT for Cancer Patients on TherapyStanford UniversityPhase 2 Completed7 enrolled 6 charts
NCT00154388 2016-11-18Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare DiseasesNovartisPhase 2 Completed185 enrolled
NCT00002475 2013-07-10Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced CancerNational Cancer Institute (NCI)Phase 2 Completed40 enrolled